GNI  Group Ltd. Logo

GNI Group Ltd.

Biopharma firm developing novel drugs for cancer and inflammatory diseases using genetics.

2160 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
中央区日本橋本町二丁目2番2号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

GNI Group Ltd. is a multinational, vertically integrated biopharmaceutical company engaged in the research, clinical development, manufacturing, and commercialization of pharmaceutical drugs and medical devices. The company focuses on developing novel treatments for intractable conditions with unmet medical needs, particularly in the areas of cancer and inflammatory diseases. With core operations spanning Japan, China, and the US, GNI Group leverages genetic analysis technology in its drug discovery pipeline. Its key commercial products include Etuary (pirfenidone) for the treatment of idiopathic pulmonary fibrosis.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for GNI Group Ltd. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-14 10:05
Regulatory News Service
確認書
Japanese 10.0 KB
2025-08-14 09:30
Interim Report
半期報告書-第25期(2025/01/01-2025/12/31)
Japanese 296.9 KB
2025-07-25 04:00
Regulatory News Service
訂正臨時報告書
Japanese 28.9 KB
2025-07-24 10:09
Regulatory News Service
訂正臨時報告書
Japanese 40.7 KB
2025-04-23 09:00
Regulatory News Service
臨時報告書
Japanese 32.7 KB
2025-03-31 09:00
Regulatory News Service
確認書
Japanese 8.2 KB
2025-03-31 09:00
Regulatory News Service
内部統制報告書-第24期(2024/01/01-2024/12/31)
Japanese 22.2 KB
2025-03-31 09:00
Annual Report
有価証券報告書-第24期(2024/01/01-2024/12/31)
Japanese 1.2 MB
2025-03-28 03:30
Regulatory News Service
臨時報告書
Japanese 21.6 KB
2024-08-14 10:08
Regulatory News Service
臨時報告書
Japanese 19.0 KB
2024-08-14 09:26
Interim Report
半期報告書-第24期(2024/01/01-2024/12/31)
Japanese 301.9 KB
2024-08-14 09:26
Regulatory News Service
確認書
Japanese 10.0 KB
2024-07-02 08:00
Regulatory News Service
訂正報告書(大量保有報告書・変更報告書)
Japanese 51.9 KB
2024-06-28 09:00
Major Shareholding Notification
大量保有報告書
Japanese 52.6 KB
2024-05-30 09:30
Regulatory News Service
臨時報告書
Japanese 32.3 KB

Automate Your Workflow. Get a real-time feed of all GNI Group Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for GNI Group Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Clinical-stage biopharma developing novel cancer drugs aiming for fewer side effects.
Japan 4575
Can-Fite BioPharma Ltd. Logo
Develops oral small-molecule drugs targeting A3AR for oncology and inflammatory diseases.
Israel CANF
Cannovum Cannabis AG Logo
Importer & producer of medical cannabis, expanding into recreational cultivation infrastructure.
Germany 27N0
Cantourage Group SE Logo
A European platform producing and distributing medical cannabis products to pharmacies.
Germany HIGH
CELADON PHARMACEUTICALS PLC Logo
Vertically integrated pharma developing cannabis medicines for chronic pain.
United Kingdom CEL
Cellectis Logo
Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.
France ALCLS
CellSeed Inc. Logo
Develops cell sheet products, culture equipment, and offers contract manufacturing services.
Japan 7776
CellSource Co.,Ltd. Logo
Processes patient-derived stem cells and PRP for regenerative therapies at medical facilities.
Japan 4880
Celon Pharma S.A. Logo
Researches, develops, and markets innovative drugs for oncology and neurology.
Poland CLN
Cessatech A/S Logo
Develops a non-invasive nasal spray for acute pain relief in children during medical procedures.
Denmark CESSA

Talk to a Data Expert

Have a question? We'll get back to you promptly.